Smithbridge Asset Management Inc. DE Acquires 2,503 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Smithbridge Asset Management Inc. DE raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 75.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,806 shares of the biopharmaceutical company's stock after purchasing an additional 2,503 shares during the period. Smithbridge Asset Management Inc. DE's holdings in Regeneron Pharmaceuticals were worth $6,103,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. SteelPeak Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc boosted its position in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock valued at $8,317,000 after purchasing an additional 941 shares in the last quarter. Tri Locum Partners LP grew its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock worth $18,410,000 after purchasing an additional 8,949 shares during the period. Nordea Investment Management AB raised its holdings in Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company's stock worth $28,218,000 after purchasing an additional 5,495 shares in the last quarter. Finally, Tidal Investments LLC lifted its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after buying an additional 711 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partners reaffirmed a "market perform" rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Piper Sandler lifted their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an "overweight" rating in a report on Friday, August 23rd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Finally, Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $4.41 on Monday, hitting $928.61. 578,674 shares of the company's stock were exchanged, compared to its average volume of 505,060. Regeneron Pharmaceuticals, Inc. has a 1 year low of $772.84 and a 1 year high of $1,211.20. The company has a 50-day simple moving average of $1,083.08 and a 200-day simple moving average of $1,041.32. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock has a market capitalization of $102.37 billion, a PE ratio of 24.59, a PEG ratio of 3.20 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the business earned $8.79 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company's stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.